These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Maxwell KN; Breslow JL Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091 [TBL] [Abstract][Full Text] [Related]
47. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels. Marais AD; Kim JB; Wasserman SM; Lambert G Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268 [TBL] [Abstract][Full Text] [Related]
48. Characterization of novel mutations in the catalytic domain of the PCSK9 gene. Cameron J; Holla OL; Laerdahl JK; Kulseth MA; Ranheim T; Rognes T; Berge KE; Leren TP J Intern Med; 2008 Apr; 263(4):420-31. PubMed ID: 18266662 [TBL] [Abstract][Full Text] [Related]
49. Atherosclerosis: cell biology and lipoproteins-focus on CD40 signaling, PCSK9, and novel animal models. Bürger C; Weber C; Lutgens E; Gerdes N Curr Opin Lipidol; 2015 Jun; 26(3):245-6. PubMed ID: 25950709 [No Abstract] [Full Text] [Related]
50. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. Sahebkar A; Watts GF Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550 [TBL] [Abstract][Full Text] [Related]
51. Regulation of proprotein convertase subtilisin/kexin type 9: therapeutical perspectives. Chan DC Atherosclerosis; 2011 Jul; 217(1):77-9. PubMed ID: 21444085 [No Abstract] [Full Text] [Related]
52. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol. Ling H; Burns TL; Hilleman DE Cardiovasc Ther; 2014 Apr; 32(2):82-8. PubMed ID: 24354905 [TBL] [Abstract][Full Text] [Related]
53. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Si-Tayeb K; Idriss S; Champon B; Caillaud A; Pichelin M; Arnaud L; Lemarchand P; Le May C; Zibara K; Cariou B Dis Model Mech; 2016 Jan; 9(1):81-90. PubMed ID: 26586530 [TBL] [Abstract][Full Text] [Related]
54. PCSK9: a promising therapeutic target for dyslipidemias? Lambert G; Krempf M; Costet P Trends Endocrinol Metab; 2006 Apr; 17(3):79-81. PubMed ID: 16487721 [TBL] [Abstract][Full Text] [Related]
55. Preserved adrenal function in fully PCSK9-deficient subject. Cariou B; Benoit I; Le May C Int J Cardiol; 2014 Sep; 176(2):499-500. PubMed ID: 25062564 [No Abstract] [Full Text] [Related]
56. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations. Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K Circ J; 2016; 80(2):512-8. PubMed ID: 26632531 [TBL] [Abstract][Full Text] [Related]
57. Novel Insights Into the Mechanisms Regulating Pro-Atrial Natriuretic Peptide Cleavage in the Heart and Blood Pressure Regulation: Proprotein Convertase Subtilisin/Kexin 6 Is the Corin Activating Enzyme. Volpe M; Rubattu S Circ Res; 2016 Jan; 118(2):196-8. PubMed ID: 26838312 [No Abstract] [Full Text] [Related]
58. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and the Future of Lipid Lowering Therapy. Joseph L; Robinson JG Prog Cardiovasc Dis; 2015; 58(1):19-31. PubMed ID: 25936907 [TBL] [Abstract][Full Text] [Related]